The bi-directional nanosystem has been exposed that FLG nanoparticles loaded with VEGF/VEGFR2 pathway inhibitors, low molecular weight heparin (LMWH), and gambogic acid (GA) and modified by F3 peptide targeting tumor vascular endothelial cells, obstructed the abnormal proliferation of vascular endothelial cells, increased pericyte coverage, and improved hypoxia, while the other nanosystem MAR/MPA with CCL5/CCR5 blocker Maraviroc induced the decrease of glycolysis rate, VEGF secretion, and Tregs recruitment as well as the increase of CD8 + T and CD4 + T cell infiltration (Deng et al., 2021). The gene discussed is CCL5; the disease is neoplasm.